Condition: Multiple Myeloma and Malignant Plasma Cell Neoplasms · Sponsor: Peking University First Hospital
Multiple Myeloma (MM), the second most common hematological malignancy, continues to pose challenges in precise clinical identification. As a potential solution, nuclear medicine immuno-PET imaging has emerged as a promising approach. However, traditional full-length antibody probes suffer from delayed tumor uptake peaks and low target-to-background ratios, limiting their clinical utility. In our study, a peptide or nanobody targeting BCMA was developed by computer-aided designing, which was subsequently radiolabeled with 68Ga to create a novel molecular probe, 68Ga-MM-BC1. This research aims to overcome the diagnostic limitations of MM and may also offer valuable insights for molecular-targeted imaging in other malignant tumors.
This description comes directly from the study's public registry record.
Tianyao Wang, PhD · 9298551137 · tianyao.wang@pkufh.com
Tingting Yuan, M.D. · 13051707479 · biluohtt@163.com
Always discuss trial participation with your own doctor first.
| Department of Nuclear Medicine, Peking University First Hospital | Beijing, Beijing Municipality, China | Recruiting |
| Peking University First Hospital | Beijing, Beijing Municipality, China | Enrolling By Invitation |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06717113